Alex Kiselyov, Konstantin V. Balakin, Sergey E. Tkachenko and Nikolay P. Savchuk Pages 711 - 717 ( 7 )
The majority of marketed and late stage development kinase inhibitors are reported to be ATPcompetitive. As a result, many promising drug candidates display non-specific activity that results in undesired physiological effects. There is growing interest towards non-ATP competitive kinase inhibitors, as they are expected to yield highly specific and efficacious molecules devoid of non-mechanistic toxicity. Recent developments in this area are summarized in our review.
Protein kinases, Tyrosine kinases, Serine/threonine kinases, Non-ATP competitive inhibitor, Allosteric binding, Library design
ChemDiv, Inc. 11558Sorrento Valley Rd., Ste. 5, San Diego, CA 92121, USA.